Education
About Us
Working with TipRanks
Follow Us
NLS Pharmaceutics (NLSP)
NASDAQ:NLSP
Total Valuation
NLS Pharmaceutics has a market cap or net worth of $8.20M. The enterprise value is $1.01B.
Market Cap$8.20M
Enterprise Value$1.01B
Share Statistics
NLS Pharmaceutics has 3,597,641 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,597,641
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NLS Pharmaceutics’s return on equity (ROE) is 1.38 and return on invested capital (ROIC) is 265.97%.
Return on Equity (ROE)1.38
Return on Assets (ROA)-6.59
Return on Invested Capital (ROIC)265.97%
Return on Capital Employed (ROCE)1.94
Revenue Per Employee0.00
Profits Per Employee-2.03M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NLS Pharmaceutics is -73.77. NLS Pharmaceutics’s PEG ratio is -16.62.
PE Ratio-73.77
PS Ratio0.00
PB Ratio309.56
Price to Fair Value-101.65
Price to FCF-73.18
Price to Operating Cash Flow-73.18
PEG Ratio-16.62
Income Statement
In the last 12 months, NLS Pharmaceutics had revenue of 0.00 and earned -12.17M in profits. Earnings per share was -0.32.
Revenue0.00
Gross Profit-11.41K
Operating Income-11.81M
Pretax Income-12.17M
Net Income-12.17M
EBITDA-11.80M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -1.53M and capital expenditures -2.00, giving a free cash flow of -1.53M billion.
Operating Cash Flow-1.53M
Free Cash Flow-1.53M
Free Cash Flow per Share-0.43
Dividends & Yields
NLS Pharmaceutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.20
52-Week Price Change-61.55%
50-Day Moving Average1.76
200-Day Moving Average2.81
Relative Strength Index (RSI)56.41
Average Volume (3m)383.61K
Important Dates
NLS Pharmaceutics upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
NLS Pharmaceutics as a current ratio of 0.23, with Debt / Equity ratio of 0.00%
Current Ratio0.23
Quick Ratio0.23
Debt to Market Cap<0.01
Net Debt to EBITDA-0.06
Interest Coverage Ratio-81.34
Taxes
In the past 12 months, NLS Pharmaceutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NLS Pharmaceutics EV to EBITDA ratio is -76.18, with an EV/FCF ratio of -92.79.
EV to Sales0.00
EV to EBITDA-76.18
EV to Free Cash Flow-92.79
EV to Operating Cash Flow-92.79
Balance Sheet
NLS Pharmaceutics has $552.76K in cash and marketable securities with $1.71M in debt, giving a net cash position of $1.16M billion.
Cash & Marketable Securities$552.76K
Total Debt$1.71M
Net Cash$1.16M
Net Cash Per Share$0.32
Tangible Book Value Per Share-$0.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NLS Pharmaceutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―